Onasemnogene abeparvovec commonly linked to hepatotoxicity
Hepatotoxicity is common after treatment with onasemnogene abeparvovec for spinal muscular atrophy, a recent study has found. Clinicians should anticipate and be ready to manage such adverse events, and be aware of any potential underlying conditions that could aggravate them.
Pancreatic enzymes supplementation leads to symptomatic recovery in sorafenib-treated HCC
Supplementation with pancreatic enzymes results in symptomatic recovery in hepatocellular carcinoma (HCC), as shown in a study that validated the association between malabsorption (MA) and pancreatic insufficiency (PI) in 10 percent of sorafenib-treated patients.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in